Our systematic GBM phenotypic discovery platform demonstrates the robustness of the FAK+MEK inhibitor combination treatment across heterogeneous GBM stem cell models, supporting the case for further preclinical development in clinical studies. The gene discussed is MAP2K7; the disease is glioblastoma.